DEF 14A: Apellis Pharmaceuticals Announces Details for 2024 Annual Stockholders Meeting

Apellis Pharmaceuticals sets date for its 2024 annual stockholders meeting, outlining key proposals including director elections, auditor ratification, and executive compensation advisory vote.

Summary

• Apellis Pharmaceuticals will hold its 2024 annual meeting of stockholders virtually on June 5, 2024.
• Stockholders of record as of April 8, 2024, are eligible to vote on several key proposals.
• The proposals include the election of two Class I directors, ratification of Deloitte & Touche LLP as the independent accounting firm, and an advisory vote on executive compensation.
• The board of directors recommends voting in favor of all listed proposals.
• In 2023, Apellis generated over $365 million in U.S. net product sales from EMPAVELI and SYFOVRE.
• SYFOVRE, a treatment for geographic atrophy, was approved by the FDA in February 2023.
• EMPAVELI continued to elevate the standard of care for patients with PNH.
• The company raised $402.5 million in gross proceeds through a public offering in February 2023.
• The company launched SYFOVRE in the United States in March 2023, delivering over 160,000 doses and generating $275.2 million in U.S. net product sales in its first 10 months.
• EMPAVELI recorded $91.0 million in U.S. net product revenue in 2023.
• The FDA approved the EMPAVELI Injector in October 2023.
• The company advanced APL-3007 into a Phase 1 clinical study.
• The company established a compliance committee of the Board of Directors.
• The company launched a series of new talent programs enabling our employees to gain a collection of experiences, knowledge, and skills that strengthen our capabilities while enabling employees to achieve their personal career interests.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook, highlighting commercial successes, pipeline advancements, and financial stability. The management's comments are optimistic, and the overall tone suggests confidence in the company's future prospects.

Positives

• Apellis achieved significant commercial success with over $365 million in U.S. net product sales in 2023.
• SYFOVRE's launch was strong, generating $275.2 million in U.S. net product sales in its first 10 months.
• EMPAVELI continues to perform well, recording $91.0 million in U.S. net product revenue in 2023.
• The company successfully raised $402.5 million through a public offering, strengthening its financial position.
• Advancement of APL-3007 into Phase 1 clinical study indicates progress in pipeline development.
• The company established a compliance committee of the Board of Directors.

Negatives

• The document does not explicitly state any negatives.

Risks

• The document does not explicitly state any risks.

Future Outlook

The company expects its growth trajectory to continue for years to come and expects cash to fund operations for the foreseeable future. Priorities for 2024 include reaching more patients with SYFOVRE, maximizing EMPAVELI in PNH, progressing systemic pegcetacoplan in C3G and IC-MPGN, and advancing the early pipeline and collaboration with Beam Therapeutics.

Management Comments

• We believe that our candor in addressing questions from the physician and patient community allowed us to recover.
• This in turn puts Apellis on solid financial ground with expected cash to fund our operations for the foreseeable future.
• We entered 2024 in a strong position, with our relentless commitment to creating even greater value for both patients and shareholders alike.
• Without question, the best is yet to come for Apellis.

Industry Context

Apellis is operating in the competitive biopharmaceutical industry, focusing on complement-mediated diseases. The company's success with SYFOVRE in geographic atrophy positions it as a leader in the ophthalmology space, while EMPAVELI addresses the rare disease market for PNH. The collaboration with Beam Therapeutics indicates a focus on innovative technologies.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• However, the document does mention that the company competes for executive talent with many public companies that are larger and more established than we are or that possess greater resources than we do, and with smaller private companies that may be able to offer greater equity compensation potential.
• The document also mentions that the company benchmarks its executive compensation against a peer group of 14 companies, including ACADIA Pharmaceuticals, Exelixis, Inc., PTC Therapeutics, Alkermes plc, Insmed Incorporated, Sarepta Therapeutics, Amicus Therapeutics, Inc., Intra-Cellular Therapies, Inc., Ultragenyx Pharmaceuticals, Blueprint Medicines, Ionis Pharmaceuticals, United Therapeutics, Corcept Therapeutics Incorporated, and Neurocrine Biosciences.

Related Party Transactions

• In the February 2023 offering, Avoro Capital Advisors LLC, Wellington Management Group, T. Rowe Price, and The Vanguard Group, which were beneficial owners of more than 5% of our voting securities prior to the February 2023 offering, purchased a pre-funded warrant for 2,300,000 shares, 1,120,000 shares, 1,011,779 shares and 90,000 shares, respectively, for approximately $144.9 million, $70.6 million, $63.7 million and $5.7 million, respectively, through the underwriters at the public offering price.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key company matters.
• Employees are impacted by talent programs and wellbeing initiatives.
• Patients benefit from the continued commercialization and development of new therapies.
• The company's financial stability impacts suppliers and creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the 2024 Annual Meeting on June 5, 2024.
• Apellis will continue to focus on commercializing SYFOVRE and EMPAVELI, advancing its pipeline, and optimizing resource allocation.

Key Dates

Keywords

Apellis, stockholders meeting, proxy statement, directors, executive compensation, Deloitte & Touche, SYFOVRE, EMPAVELI, APL-3007, FDA, net product sales, financial results